Melatonin agonists in the treatment of insomnia and depression
DOI:
https://doi.org/10.25118/2236-918X-4-3-2Keywords:
Melatonin, Insomnia, Major Depressive DisorderAbstract
Insomnia and depression are very common conditions of morbidity and mortality in general population. The concurrence of both conditions simultaneously in the same patient is very often. There are several available agents for their treatments, but side effects and poor response are the reasons for abandoning therapy. The understanding of the physiology of daytime rhythm over sleep and humor has led to the study of melatonin and its analogs. They propose the treatment of both conditions with a different mechanism of action from the present options for clinical use. The role of melatonin and its analogs is the objective of this review.
Downloads
Metrics
References
Cardinali DP et al. Melatonin and its analogs in insomnia and depression. J Pineal Res. 2012; 52:365-75. https://doi.org/10.1111/j.1600-079X.2011.00962.x
American Psychiatric Association (APA).Diagnostic and statistical manual of mental disorders. Fifth ed. Washington: The American Psychiatric Association; 2013. https://doi.org/10.1176/appi.books.9780890425596
Sivertsen B. Disturbed sleep as a predictor of sickness absense and disability retirement. Symposium S08: Work and disturbed sleep: determinants and consequences. Presented at SLEEP 26th Annual Meeting of the Associated Professional Sleep Societies LLC; jun. 9-13 de 2012; Boston, 2012.
Barros CASM de, Grandi AR. Sinais e sintomas geriátricos: a insônia no idoso. In: Terra NL, Silva R, SchimidtOF. Tópicos em Geriatria II. Porto Alegre: Edipucrs, 2007:81-92.
CordioliAV et al. Psicofármacos: consulta rápida. 4 ed. Porto Alegre: Artmed, 2011.
Sarsour K et al. Association of insomnia severity and comorbid medical and psychiatric disorders in a health plan-based sample: Insomnia severity and comorbidities. Sleep Med. Jan 2010; 11:69-74. https://doi.org/10.1016/j.sleep.2009.02.008
NowellPD, BuysseDJ. Treatment or insomnia in patients with mood disorders. Depress Axiety. 2001; 14:7-18. https://doi.org/10.1002/da.1042
Classificação de Transtornos mentais e de Comportamento da CID-10: Descrições Clínicas e Diretrizes Diagnósticas - Coord. Organiz. Mund. da Saúde; trad. Dorgival Caetano. - Porto Alegre: Artmed, 1993.
WHO. Depression. 2013 [acessado em 11.08.2013]. Disponível em: http://www.who.int/mental_health/management/depression/definition/en/index.html
CryanJF et al. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci. 2002; 23:238-45. https://doi.org/10.1016/S0165-6147(02)02017-5
TurekFW. From circadian rhythms to clock genes in depression. Int Clin Psychopharmacol. 2007; 22:S1-8. https://doi.org/10.1097/01.yic.0000277956.93777.6a
Rahman SA et all. Antidepressant action of melatonin in the treatment of Delayed Sleep Phase Syndrome. Sleep Medicine. 2010; 11:131-36. https://doi.org/10.1016/j.sleep.2009.07.013
Lader M. Limitations of current medical treatments for depression: disturbed circadian rhythms as a possible therapeutic target. Eur Neuropsychopharmacol. 2007; 17:743-55. https://doi.org/10.1016/j.euroneuro.2007.05.004
Detanico BC et al. Antidepressant-like effects of melatonin in the mouse chronic mild stress model. European Journal of Pharmacology. 2009; 607:121-5. https://doi.org/10.1016/j.ejphar.2009.02.037
Rahman SA et al. Altered Sleep architecture and higher incidence of subsyndromal depression in low endogenous melatonin secretors. Eur Arch Psychiatry Clin Neurosci. 2010 Jun; 260(4):327-35.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria allows the author (s) to keep their copyrights unrestricted. Allows the author (s) to retain their publication rights without restriction. Authors should ensure that the article is an original work without fabrication, fraud or plagiarism; does not infringe any copyright or right of ownership of any third party. Authors should also ensure that each one complies with the authorship requirements as recommended by the ICMJE and understand that if the article or part of it is flawed or fraudulent, each author shares responsibility.
Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) - Debates em Psiquiatria is governed by the licencse CC-By-NC
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
